Evolent Health (FRA:9EH) Cyclically Adjusted Revenue per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9EH Evolent Health Inc FRA:9EH
65 GF Score
Price €3.10
GF Value €9.09
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Evolent Health Cyclically Adjusted Revenue per Share?

Evolent Health FRA:9EH +21.09% 65 Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus rates FRA:9EH with a GF Score™ of 65/100 and a GF Value™ of €9.09 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Evolent Health's adjusted revenue per share for the three months ended in Jun. 2026 was €5.033. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Evolent Health's average Cyclically Adjusted Revenue Growth Rate was 13.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-08), Evolent Health's current stock price is €3.10. Evolent Health's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.00. Evolent Health's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evolent Health was 3.23. The lowest was 0.16. And the median was 0.81.


Evolent Health  (FRA:9EH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evolent Health was 3.23. The lowest was 0.16. And the median was 0.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Evolent Health Cyclically Adjusted Revenue per Share Related Terms


Evolent Health Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Evolent Health's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolent Health Cyclically Adjusted Revenue per Share Chart

Evolent Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 9.75 11.64 11.74

Evolent Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.97 11.76 11.74 11.84 0.00

FRA:9EH vs NRC, SOPH, WEAV: Cyclically Adjusted Revenue per Share Comparison

For the Health Information Services subindustry, Evolent Health's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolent Health Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evolent Health's Cyclically Adjusted PS Ratio falls into.


FRA:9EH
65GF Score
Evolent Health Inc FRA:9EH
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolent Health Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evolent Health's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.033/333.9520*333.9520
=5.033

Current CPI (Jun. 2026) = 333.9520.

Evolent Health Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.244 241.428 1.721
201612 1.597 241.432 2.209
201703 1.888 243.801 2.586
201706 1.602 244.955 2.184
201709 1.287 246.819 1.741
201712 1.285 246.524 1.741
201803 1.503 249.554 2.011
201806 1.600 251.989 2.120
201809 1.648 252.439 2.180
201812 2.156 251.233 2.866
201903 2.206 254.202 2.898
201906 2.064 256.143 2.691
201909 2.385 256.759 3.102
201912 0.828 256.974 1.076
202003 2.361 258.115 3.055
202006 2.261 257.797 2.929
202009 2.388 260.280 3.064
202012 2.206 260.474 2.828
202103 2.134 264.877 2.691
202106 2.157 271.696 2.651
202109 2.204 274.310 2.683
202112 2.488 278.802 2.980
202203 3.013 287.504 3.500
202206 3.360 296.311 3.787
202209 3.586 296.808 4.035
202212 3.615 296.797 4.068
202303 3.706 301.836 4.100
202306 3.891 305.109 4.259
202309 4.264 307.789 4.626
202312 4.488 306.746 4.886
202403 5.156 312.332 5.513
202406 5.242 314.175 5.572
202409 4.874 315.301 5.162
202412 5.368 315.605 5.680
202503 3.880 319.799 4.052
202506 3.324 322.561 3.441
202509 3.582 324.800 3.683
202512 3.587 324.054 3.697
202603 3.836 330.213 3.879
202606 5.033 333.952 5.033

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Evolent Health (FRA:9EH) has a Cyclically Adjusted Revenue per Share of €0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Evolent Health and its competitors.
Is Evolent Health's Cyclically Adjusted Revenue per Share too high?
Evolent Health's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Evolent Health has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's Cyclically Adjusted Revenue per Share compare to NRC and SOPH?
Evolent Health's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Evolent Health and its competitors. Evolent Health's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (FRA:9EH) is currently considered Possible Value Trap. The stock's GF Value™ is €9.09, compared to a current price of €3.10 — trading 65.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Evolent Health's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Evolent Health (FRA:9EH), the current Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolent Health (FRA:9EH) Overvalued in 2026?

Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued. The current stock price of €3.10 is trading 65.9% below its estimated GF Value™ of €9.09. GuruFocus considers Evolent Health to be Possible Value Trap.

Key valuation signals for FRA:9EH:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €9.09 vs. price of €3.10 (65.9% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the FRA:9EH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evolent Health Business Description

Other Exchanges EVH:USA9EH:Germany
Address 1812 North Moore Street, Suite 1705, Arlington, VA, USA, 22209
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
65GF Score

Get the complete analysis for FRA:9EH

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10
Price
€9.09
GF Value